NASH Archives

Best in Biotech 21 Dec 2023

Five companies racing to bring their NASH treatments toward the finish line

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), where fat builds up on the liver, potentially leading to liver damage or cirrhosis. With no U.S. Food and Drug Administration (FDA)-approved treatments for the disease, many NASH companies are currently attempting to bring their candidates toward approval. In this article, we take a […]

December 21, 2023 - 7 minutesmins - By Willow Shah-Neville

In Depth 19 Oct 2023

Biotech’s battle against NASH: The ongoing pursuit of an effective treatment

NASH is one of the most common reasons for a patients receiving a liver transplant. The condition is a severe form of non-alcoholic fatty liver disease (NAFLD), whereby fat builds up on the liver, potentially leading to liver damage or cirrhosis. And, yet, despite the severity of the disease, there are still no approved NASH […]

October 19, 2023 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 15 Sep 2023

Five latest advancements in NASH research

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) – a condition where fat builds up in the liver, potentially causing liver damage or cirrhosis. Despite the severity of the disease, and the fact that approximately 25% of U.S. adults have NAFLD, while 5% have NASH, there is yet to be […]

September 15, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 3 May 2023

First drug discovered through 3D bioprinted tissue disease model

Viscient Bio, Inc. has announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease formed from human cells. The company said it expects to develop the drug to treat non-alcoholic steatohepatitis (NASH), a growing epidemic disease that is believed to affect more than 10% of the U.S. […]

May 3, 2023 - 3 minutesmins - By Jim Cornall

More News! 4 Nov 2022

Alimentiv and Summit collaborate to tackle liver disease NASH

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

November 4, 2022 - 3 minutesmins - By Liza Laws

More News! 16 Sep 2022

Strategic collaboration for drug to treat NASH, obesity and diabetes announced

A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes has been agreed. NeuroBo Pharmaceuticals and Dong-A ST Co., announced their strategic collaboration today (September 16) for DA-1241 and DA-1726 which are currently being evaluated for treatment. DA-1241 is a novel G-Protein-Coupled Receptor […]

September 16, 2022 - 4 minutesmins - By Liza Laws

Liver body Promethera decade3d anatomy online 1

News and Trends 5 Jul 2022

Poxel publishes ALD studies

Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The articles have been about genetic disease X-Linked Adrenoleukodystrophy (ALD) and molecules PXL065 and PXL770. These molecules have separate […]

July 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 May 2020

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

Patients with the chronic liver disease NASH must now wait even longer for an approved treatment, after French biotech Genfit’s phase III trial of its lead drug candidate elafibranor failed. But, newer players, such as Novo Nordisk, are edging closer to the market. This year, it is predicted that NASH — the full name of […]

May 13, 2020 - 4 minutesmins - By Helen Albert

nash northsea therapeutics, liver disease, disease modeling

News and Trends 8 Jan 2020

NorthSea Therapeutics Raises €36M to Complete NASH Phase II Trial

The Dutch biotech NorthSea Therapeutics has raised a €36M ($40M) Series B round to fund the end of a phase IIb trial of its lead fatty acid drug to treat the liver condition NASH, as well as advancing two other drugs to clinical trials. There were two newcomers to the round: the US investor venBio […]

January 8, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

December 17, 2019 - 2 minutesmins - By Jonathan Smith

Interview 30 Jul 2019

The First Approved NASH Therapy?

Genfit is poised to become the first company to get a treatment for NASH to market — something that could happen as early as 2020, should its late 2019 phase III trial results be positive. I spoke to Dean Hum, the current COO and CSO of Genfit, to find out more about the company’s 20-year […]

July 30, 2019 - 6 minutesmins - By Helen Albert

nash liver fibrosis genfit terns pharmaceuticals organ

News and Trends 25 Jun 2019

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for the chronic liver disease NASH in China. As part of the deal, Genfit will receive a €31M ($35M) upfront fee and up to €170M ($193M) in developmental milestone payments. The two companies will also collaborate on other development programs for […]

June 25, 2019 - 3 minutesmins - By Jonathan Smith

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

NASH

Five companies racing to bring their NASH treatments toward the finish line

Biotech’s battle against NASH: The ongoing pursuit of an effective treatment

Five latest advancements in NASH research

First drug discovered through 3D bioprinted tissue disease model

Alimentiv and Summit collaborate to tackle liver disease NASH

Strategic collaboration for drug to treat NASH, obesity and diabetes announced

Poxel publishes ALD studies

Genfit’s Phase III Drug Fails to Treat NASH, But New Players On Horizon

NorthSea Therapeutics Raises €36M to Complete NASH Phase II Trial

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

The First Approved NASH Therapy?

Genfit’s NASH Drug to Be Developed in China in Deal Worth up to €200M

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!